The Skinny on Weight Loss Drugs

The new class of weight loss drugs melts away excess pounds, but could its effects spill beyond the health care industry?

As the obesity epidemic rages across the globe, new weight loss drugs have become so popular that some manufacturers are unable to meet patient demand. Dr. David Katz, founder and CEO of Diet ID, joins Double Take to discuss investment ramifications of these hotly demanded medications.

PRESENTED BY

Raphael J. Lewis

Head of specialist research

Jack Encarnacao

Research analyst, investigative, Specialist Research team

TOPICS

Themes

Replay: Newton's Top Market Predictions for 2026

Watch our virtual roundtable, where BNY Investments Newton’s portfolio managers and analysts debate their most compelling, off-consensus predictions.

December 15, 2025

Beyond the Boom: Where Value Emerges

Unlocking value in AI's third wave.

September 30, 2025 Chris Hazelton Newton US large cap value & income team

Diving into DeepSeek: Disruption in the AI Sector?

We examine the possible implications of DeepSeek’s potentially ground-breaking innovation.

February 20, 2025 Robert C Zeuthen Newton secular research team

RELATED CONTENT

Replay: Newton's Top Market Predictions for 2026

Watch our virtual roundtable, where BNY Investments Newton’s portfolio managers and analysts debate their most compelling, off-consensus predictions.

December 15, 2025

Beyond the Boom: Where Value Emerges

Unlocking value in AI's third wave.

September 30, 2025 Chris Hazelton Newton US large cap value & income team

Diving into DeepSeek: Disruption in the AI Sector?

We examine the possible implications of DeepSeek’s potentially ground-breaking innovation.

February 20, 2025 Robert C Zeuthen Newton secular research team

See all insights

EXPLORE TOPICS